$1.35
-0.03 (-2.17%)
Open$1.36
Previous Close$1.38
Day High$1.38
Day Low$1.30
52W High$2.23
52W Low$0.85
Volume—
Avg Volume151.3K
Market Cap32.93M
P/E Ratio—
EPS$-0.41
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,220.0% upside
Current
$1.35
$1.35
Target
$31.32
$31.32
$21.60
$31.32 avg
$37.71
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.32M | 9.26M | 9.19M |
| Net Income | 712.1K | 643.5K | 610.9K |
| Profit Margin | 7.6% | 7.0% | 6.7% |
| EBITDA | 971.8K | 983.2K | 961.2K |
| Free Cash Flow | 631.5K | 606.6K | 819.9K |
| Rev Growth | +16.1% | +5.9% | +8.5% |
| Debt/Equity | 1.16 | 1.10 | 1.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |